The Online Investor
OLI Premium
Retiree Portfolio
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
ChartZero

Slideshow Secondary Stock Offerings

By The Online Investor Staff, updated Fri., Jul. 1, 7:38 AM

Slide #17. Medgenics, Inc. Secondary Offering

Company: Medgenics, Inc. (AMEX:MDGN)
Date announced: 6/20/2016
Shares Offered: 3,640,000
Date of Pricing: 6/21/2016
Price Per Share: $5.50
Secondary Offering Details: Medgenics, Inc. (NYSE: MDGN), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell shares of its common stock in an underwritten public offering pursuant to an existing shelf registration statement. All of the shares to be sold in the proposed offering are being sold by Medgenics. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. -updated 6/21 - Medgenics, Inc. (NYSE MKT: MDGN) today announced the pricing of 3,640,000 shares of its common stock in a previously announced underwritten public offering at a price to the public of $5.50 per share. In connection with the offering, Medgenics has also granted the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered to the public. Gross proceeds to Medgenics from the sale of shares are expected to be approximately $20 million, excluding any exercise of the underwriters' option to purchase up to an additional 546,000 shares of common stock. If the underwriters' option is exercised in full, gross proceeds will be approximately $23 million. The offering is expected to close on or about June 24, 2016 subject to customary closing conditions.

Medgenics is a clinical stage rare and orphan disease company developing a proprietary ex vivo gene therapy platform. Co.'s TARGT™ (Transduced Autologous Restorative Gene Therapy) platform is designed to provide sustained protein and peptide therapies to treat a range of diseases and conditions. Co. is studying its primary product, MDGN-201, which it refers to as TARGTEPO™, in a Phase 1/2 clinical trial in patients with End Stage Renal Disease (ESRD), and it plans on studying TARGTEPO in identified orphan populations of unmet need including subpopulations of Chronic Kidney Disease or ESRD patients who may benefit from treatment with TARGTEPO.

MDGN SEC Filing Email Alerts Service

Open the MDGN Page at The Online Investor »

Company Name:  Medgenics Inc
Website:  www.medgenics.com
Sector:  Biotechnology
Number of ETFs Holding MDGN:  14
Total Market Value Held by ETFs:  $3.54M
Total Market Capitalization:  $175.00M
% of Market Cap. Held by ETFs:  2.02%
 

Open the MDGN Page at The Online Investor (in a new window) »

July 1, 2016    7:38 AM Eastern
Quotes delayed 20 minutes



Strong Buy (3.50 out of 4)
69th percentile
(ranked higher than approx. 69% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite

Secondary Stock Offerings | www.TheOnlineInvestor.com | Copyright © 1998 - 2016, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.